While current immunotherapies work relatively well for patients whose tumors are already infiltrated by “killer” T cells characterized by the CD8 marker. However, a substantial fraction of patients lack these “killer” T cells in their tumors, which may result in these immunotherapies being ineffective. Recently, a new group of tumor-infiltrating immune cells—innate-like T cells (ILTCs)—were identified in breast tumors. These ILTCs are in close contact with tumor cells and can readily kill them. To evaluate the potential clinical value of these ILTCs, Dr. Chun Chou is investigating how they develop and what signals enable their robust anti-tumor activity. As a result, Dr. Chou’s work has the potential to not only broaden our understanding of how the immune system as a whole interacts with and surveys tumors, but also pave the way for novel immunotherapy strategies that harness ILTCs.
Projects and Grants
Origin and regulation of innate-like T cell responses in cancer
Memorial Sloan Kettering Cancer Center | Breast Cancer | 2018 | Ming O. Li, Ph.D.
Let's spread the word about Immunotherapy! Click to share this page with your community.